The primary research interest in growth hormone peptides centers on body composition effects specifically, the potential for simultaneous fat reduction and lean mass preservation or gain (body recomposition)
High-risk patient factors include active gastrointestinal symptoms (odds ratio 7.66, 95% confidence interval 3.4217.17), early treatment phase (less than 4 weeks), higher medication doses, pre-existing diabetic gastroparesis, obesity (BMI greater than 30), and gastroesophageal reflux disease [31]
Breton-Romero R, Weisbrod RM, Feng B, et al
These trials used longer-acting GLP-1 receptor agonists, Gloyn said, which may help counter GLP-1 resistance
We understand that taking charge of your health, whether through managing diabetes or achieving sustainable weight loss, is a profoundly personal and often transformative experience